AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is GBX 7,542.80 ($97.81).

A number of analysts have recently commented on the stock. Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Friday, March 7th. Berenberg Bank reiterated a “buy” rating and issued a GBX 140 ($1.82) price target on shares of AstraZeneca in a research note on Monday, January 27th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th.

AstraZeneca Stock Performance

Shares of AZN stock opened at £118.08 ($153.11) on Friday. AstraZeneca has a 12 month low of GBX 9,670 ($125.39) and a 12 month high of £133.88 ($173.60). The stock has a market cap of £227.19 billion, a PE ratio of 32.37, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The company’s fifty day moving average price is £115.20 and its 200-day moving average price is £113.44.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.